Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Employees - 11, CEO - James Brian Windsor, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -23.95, Piotroski Score(max is 10): 1, Working Capital: $-1854000, Total Assets: $24158000, Retained Earnings: $-401271000, EBIT: -21931000, Total Liabilities: $7240000, Revenue: $0

AryaFin Target Price - $0.12 - Current Price $ - Analyst Target Price $